Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has released an update on strategic initiatives related to its MINDCURE Research and MINDCURE Technology divisions. According to the company, its synthetic ibogaine efforts, which were announced in March 2021, include the application for two patents and the initiation of production of Good Laboratory Practice (“GLP”) ibogaine leading to the production of Good Manufacturing Practice (“GMP”) ibogaine. The company is on schedule to provide GLP supply to research partners by Q2 2022. The company is in the process of preparing to ship ibogaine drug material to its preclinical research partner. In addition, MINDCURE has wrapped up its draft research protocol for the use of MDMA and psychotherapy to treat female sexual hypoactive desire disorder. The company anticipates scheduling a pre-IND meeting with the FDA in the first quarter of 2022 with a phase 2 trial expected to commence by third quarter 2022. Regarding iSTRYM, its digital therapeutics (“DTx”) technology, MINDCURE noted that it has released the minimum viable product (“MVP”) of the tech into partner clinics across North America, exceeded its target and timeline of 10 clinics by the end of 2021. “We are proud to report that MINDCURE’s core research programs are progressing rapidly, showcasing our disciplined commitment to advancing MINDCURE’s drug research and commercial production programs,” said Mind Cure Health president and CEO Kelsey Ramsden in the press release. “Concurrently, we maintain a focus on identifying opportunities to expand our drug-development pipeline.”
To view the full press release, visit https://ibn.fm/Bv1h8
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php